Abstracts presented at SfN Neuroscience 2019 provide insight into how gene therapy advancements could be used treat diseases such as Parkinson’s and Alzheimer’s in the future.
Browsing: Parkinson’s disease
In a large data study, researchers discover that terazosin, a drug typically used to treat enlarged prostate, might be able to slow down neurodegeneration in Parkinson’s disease.
What have been the biggest headlines in industry this week? Take a look at our highlights including positive news about two monoclonal antibodies for relapsing multiple sclerosis and neuromyelitis optica spectrum disorder.
Researchers have identified that α-synuclein plays a role in DNA repair in neurons and that disruption of this function could lead to widespread death of neurons.
Ponesimod hits key endpoints in clinical trial for relapsing multiple sclerosis: industry news round-up
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
A peek behind the paper – Sarah Hamm-Alvarez on oligomeric α-synuclein in basal tears of Parkinson’s patients
Take a look behind the scenes of a recent paper in Biomarkers in Medicine as we ask the author about oligomeric α-synuclein in basal tears of Parkinson’s patients.
A new mouse model of Parkinson’s has demonstrated how the disease could spread from the gut to the brain through the vagus nerve.
Researchers have identified the earliest signs of Parkinson’s disease in the brain, many years before patients show any symptoms.
In this interview, Anders Björklund speaks to us about how we might overcome the current limitations of using stem cell therapies for Parkinson’s disease.
Researchers from the University of Oregon (OR, USA) suggest that noninvasive EEG readings could present as easily detectable biomarkers to help diagnose and improve treatment for Parkinson’s and other motor disorders.